Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,487.00    30.00 (2.06%)
Bid:
1,481.00
Ask:
1,483.00
Spread: 2.00 (0.135%)
Market Cap: £3.15b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Block listing Interim Review

4 Oct 2021 09:55

RNS Number : 9028N
Hikma Pharmaceuticals Plc
04 October 2021
 

Hikma Pharmaceuticals PLC

 

 

Block Listing Six Monthly Return

 

Date: 4 October 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

 

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

 

Block Listing Six Monthly Return

 

Date: 4 October 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

LTIP: 57,502 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

LTIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

LTIP: 0 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

LTIP: 57,502 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 4 October 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("2009 MIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

2009 MIP: 136,182 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2009 MIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2009 MIP: 136,182 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2009 MIP: 0 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 4 October 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("2018 MIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

2018 MIP: 1,000,000 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2018 MIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2018 MIP: 226,506 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2018 MIP: 773,494 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 4 October 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

EIP: 1,239,967 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

EIP: 350,000 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

EIP: 340,434 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

EIP: 1,249,533 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

LEI: 549300BNS685UXH4JI75

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRUPGCAUUPGURC
Date   Source Headline
29th May 20149:45 amRNSDirector/PDMR Shareholding
29th May 20149:40 amRNSDirector/PDMR Shareholding
28th May 201412:00 pmRNSAcquisition
27th May 20149:53 amRNSDirector/PDMR Shareholding
15th May 20143:05 pmRNSResults of AGM
15th May 20147:00 amRNSInterim Management Statement
6th May 20141:03 pmRNSDirector/PDMR Shareholding
17th Apr 20144:41 pmRNSAnnual Information Update
14th Apr 20145:28 pmRNSDirector/PDMR Shareholding
7th Apr 20145:28 pmRNSBlocklisting Interim Review
7th Apr 20144:27 pmRNSTotal Voting Rights
2nd Apr 20147:00 amRNSSuccessful resolution to US FDA warning letter
24th Mar 201410:23 amRNSDirector/PDMR Shareholding
12th Mar 20147:10 amRNSDirectorate Change
12th Mar 20147:00 amRNSFinal Results
27th Feb 20142:35 pmRNSNotification of major interests in shares
21st Feb 201410:24 amRNSBlock Listing of Shares
14th Feb 20147:00 amRNSTrading Statement
30th Dec 20139:50 amRNSDirector/PDMR Shareholding
20th Dec 20134:23 pmRNSDirector/PDMR Shareholding
20th Dec 20131:58 pmRNSDirector/PDMR Shareholding
16th Dec 20137:00 amRNSTotal Voting Rights
13th Dec 20137:00 amRNSHolding(s) in Company
20th Nov 20137:00 amRNSRe Agreement
11th Nov 20134:55 pmRNSDirector/PDMR Shareholding
8th Nov 20133:04 pmRNSDirector/PDMR Shareholding
8th Nov 20137:00 amRNSInterim Management Statement
25th Oct 20134:13 pmRNSDirector/PDMR Shareholding
23rd Oct 201311:40 amRNSHolding(s) in Company
18th Oct 20134:55 pmRNSDirector/PDMR Shareholding
4th Oct 20132:01 pmRNSDividend Declaration
1st Oct 201311:27 amRNSBlocklisting Interim Review
1st Oct 201311:22 amRNSTotal Voting Rights
18th Sep 20137:00 amRNSHikma entering Ethiopian pharmaceutical market
2nd Sep 20133:06 pmRNSTransaction in Own Shares
29th Aug 201311:10 amRNSTransaction in Own Shares
21st Aug 20137:00 amRNSInterim Results
31st Jul 20133:41 pmRNSDirector/PDMR Shareholding
19th Jul 20139:40 amRNSTotal Voting Rights
8th Jul 20137:00 amRNSTrading Statement
5th Jul 20134:21 pmRNSHolding(s) in Company
1st Jul 20137:00 amRNSSigning of Exclusive Agreement with Theravance
20th Jun 20133:16 pmRNSDirector/PDMR Shareholding
3rd Jun 201311:24 amRNSTotal Voting Rights
28th May 20135:24 pmRNSHolding(s) in Company
23rd May 20134:59 pmRNSDirector/PDMR Shareholding
21st May 20133:36 pmRNSDirector/PDMR Shareholding
20th May 20139:42 amRNSDirector/PDMR Shareholding
16th May 20133:32 pmRNSResult of AGM
16th May 20137:00 amRNSInterim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.